Bevacizumab, CAS 216974-75-3

Product Description: Bevacizumab, a humanized IgG1 monoclonal antibody, specifically binds to all VEGF-A isoforms with high affinity.

Applications: Cancer-Kinase/protease

Formula: N/A

References: [1]Tan H, et al. 99mTc-labeled bevacizumab for detecting atherosclerotic plaque linked to plaque neovascularization and monitoring antiangiogenic effects of treatment in ApoE-/-mice. Sci Rep. 2017 Jun 14;7(1):3504./[2]Wang Q, et al. Pharmacological characteristics and efficacy of a novel anti-angiogenic antibody FD006 in corneal neovascularization. BMC Biotechnol. 2014 Feb 27;14:17./[3]Di Mauro C, et al. Hedgehog signalling pathway orchestrates angiogenesis in triple-negative breast cancers. Br J Cancer. 2017 May 23;116(11):1425-1435.

CAS Number: 216974-75-3

Molecular Weight: 149 kDa(Average)

Compound Purity: 99.0

Research Area: Cancer

Solubility: H2O

Target: VEGFR

• Artikelnummer: MEXHY-P9906-5
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-P9906-5
• Green Labware: Nein
• Verpackungseinheit: 5 mg
• Mengeneinheit: STK